Compounding Pharmacies Jump on Shortage Opportunity In 2022, the FDA added Eli Lillys Zepbound and Novo Nordisks Wegovyalong with their sister GLP-1s for diabetes, Mounjaro and Ozempic, respectivelyto its list of drugs in shortage, opening the door for compounding pharmacies to legally produce compounded versions for patients who were not able to source branded products
In addition to dietary and pharmaceutical influences, new research confirms that GLP-1 secretion is impacted by sex as well as many personal health factors, including glucose tolerance and overall metabolic health, body weight, microbiome composition, and even eating behaviour itself (Huber et al., 2024)
Liraglutide shows dose-dependent nausea ratesVictoza (for diabetes) has rates around 10-17% depending on dose, while Saxenda (3.0 mg for weight management) has significantly higher nausea rates of approximately 39% according to its SmPC
coli MG1655 to obtain the mutant strain MG001, and the l-cysteine degradation ability was compared with the wild type strain (Fig
